Overview

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
Phase:
PHASE3
Details
Lead Sponsor:
Dr. Falk Pharma GmbH